Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.33 |
| ▸ | DHFR | P00374 | 3/20 | 0.32 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4706005 | 0.88 | DHFR (0.44) | DHFRSLC2A1 | |
| SCHEMBL4706351 | 0.84 | DHFR (0.32) | DHFRSLC2A1 | |
| SCHEMBL4706916 | 0.83 | PDGFRB (0.33) | APPDHFRPTPN1 | |
| SCHEMBL4705692 | 0.82 | ADORA2A (0.38) | DHFR | |
| SCHEMBL4705961 | 0.81 | DHFR (0.35) | DHFRPTPN1 | |
| SCHEMBL4707600 | 0.79 | PTPN1 (0.47) | APPDHFRSLC2A1PTPN1 | |
| SCHEMBL4706514 | 0.76 | PTPN1 (0.38) | APPDHFRPTPN1 | |
| SCHEMBL4707419 | 0.75 | PTPN1 (0.39) | APPPTPN1 | |
| Trifluoroacetic Acid SCHEMBL4707814 | 0.74 | KMT2A (0.37) | DHFRPTPN1 | |
| SCHEMBL4707075 | 0.74 | DHFR (0.40) | APPDHFRPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633754-B1 | DIAMINOPYRROLOQUINAZOLINES COMPOUNDS AS PROTEIN TYROSINE PHOSPHATASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-06-11 | — | — | EP | claimed |
| US-7226915-B2 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2007-06-05 | — | — | US | claimed |
| US-20040229890-A1 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | BERTHEL STEVEN JOSEPH (US) | 2004-11-18 | — | — | US | claimed |
| EP-1633754-B1 | DIAMINOPYRROLOQUINAZOLINES COMPOUNDS AS PROTEIN TYROSINE PHOSPHATASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-06-11 | — | — | EP | disclosed |
| US-7226915-B2 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-7226915-B2 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-7226915-B2 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-20040229890-A1 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | BERTHEL STEVEN JOSEPH (US) | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229890-A1 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | PTPN5, PTPRO, PTPN18 | APP 3706/4885DHFR 531/4885SLC2A1 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.